logo
Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?

Register
    

 


IPO Report: Fate Therapeutics (FATE)

By  +Follow September 18, 2013 7:01AM
Share:
Tickers Mentioned:

Fate Therapeutics ($FATE) is a clinical-stage biopharmaceutical company engaged in the discovery and development of pharmacologic modulators of adult stem cells to treat orphan diseases, including certain hematologic malignancies, lysosomal storage disorders and muscular dystrophies.

FATE is one of nine IPOs scheduled for this week, 11 for next week. The full IPO calendar can be found at IPOpremium

FATE is based in San Diego, CA, and scheduled a $60 million IPO with a market capitalization of $219 million at a price range mid-point of $13, for Thursday, September 19, 2013.

The S-1 was filed September 3, 2013.  FATE's manager & joint managers are Cowen; BMO Capital
Co-Managers: Wedbush PacGrow Life Sciences.

Summary

The lead product candidate from this platform, ProHema, is a pharmacologically modulated HSC therapeutic derived from umbilical cord blood.

ProHema has the potential to improve patient outcomes by enhancing hematopoietic reconstitution through accelerated and durable engraftment, facilitating greater donor matching flexibility, reducing the risk of major side effects, and enabling the use of less toxic conditioning regimens.

FATE recently exhibited a more than two-fold improvement in engraftment over the prior media formulation, and is pausing a Phase 2 clinical trial up update and incorporate a new formulation, see 'Clinical trials' below.

Valuation

Valuation Ratios

IPO Mrkt

Price /

Price /

Price /

Price /

% offered

annualizing June 6 mos '13

Cap (MM)

Sls

Erngs

BkVlue

TanBV

in IPO

Fate Therapeutics

$219

136.9

-12.2

3.0

3.0

27%

Accumulated deficit of -$75 million

Glossary

Conclusion

Buy FATE, based on the IPO, based on the relatively low price-to-book of 3, and based on the expected improved outcomes from the current Phase 2 clinical trial.

Business

FATE is a clinical-stage biopharmaceutical company engaged in the discovery and development of pharmacologic modulators of adult stem cells to treat orphan diseases, including certain hematologic malignancies, lysosomal storage disorders and muscular dystrophies.

FATE's novel approaches utilize established pharmacologic modalities, including small molecules and therapeutic proteins, and target well-characterized biological mechanisms to enhance the therapeutic potential of adult stem cells.

FATE has built two platforms that optimize the activity of adult stem cells using both ex vivo and in vivo techniques: the HSC modulation platform and SSC modulation platform.

FATE believes that the product candidates generated by its platforms have significant potential as life-changing or curative therapeutics across a broad range of orphan indications.

Modulation Platform

The HSC modulation platform focuses on the ex vivo pharmacologic optimization of hematopoietic stem cells, or HSCs.

The lead product candidate from this platform, ProHema, is a pharmacologically modulated HSC therapeutic derived from umbilical cord blood. FATE has established human proof-of-concept for ProHema in a Phase 1b clinical trial by demonstrating enhanced engraftment.

FATE is presently advancing ProHema in Phase 2 clinical development for hematologic malignancies. The SSC modulation platform focuses on the in vivo pharmacologic activation of satellite stem cells, or SSCs. FATE has identified Wnt7a as a natural promoter of SSCs to drive muscle regeneration, and FATE has demonstrated proof-of-concept of Wnt7a analogs as potential therapeutics for muscular dystrophy in preclinical animal studies. FATE is presently advancing our Wnt7a analogs in preclinical development with the goal of filing an IND in 2014.

Collaboration Revenue

Collaboration revenues are generated exclusively from a collaboration arrangement with Becton, Dickinson ($BDX) which has a market capitalization of $19 billion.

FATE is entitled to receive research funding for the conduct of joint development activities for a period of three years ending in September 2013. In addition, FATE is eligible to receive certain commercialization milestones and royalties on the sale of iPSC reagent products.

In connection with the arrangement with BD, FATE recognized $0.8 million, $1.3 million, $0.9 million and $0.4 million for the years ended December 31, 2011 and 2012 and the six months ended June 30, 2012 and 2013, respectively, as collaboration revenue.

The three-year joint development period under the license and collaboration agreement with BD concludes in September 2013.

FATE does not currently anticipate generating any significant revenues associated with iPSC tools and technologies thereafter.

ProHema Product Candidate

Lead product candidate is in clinical trials
Other product candidates are in the pre-clinical phase

ProHema is a pharmacologically-modulated HSC therapeutic derived from umbilical cord blood. It is manufactured in the transplant center by modulating an umbilical cord blood unit with FT1050 to create a final HSC therapeutic. The HSC modulation process takes only two hours, can be performed directly in the transplant center, does not require significant changes to existing infrastructure and is compatible with standard of care treatment modalities.

ProHema has the potential to improve patient outcomes by enhancing hematopoietic reconstitution through accelerated and durable engraftment, facilitating greater donor matching flexibility, reducing the risk of major side effects, and enabling the use of less toxic conditioning regimens.

Clinical trials

In a Phase 1b clinical trial in adult patients with hematologic malignancies, treatment with ProHema demonstrated a statistically significant improvement in time to engraftment of neutrophils, a type of white blood cell primarily involved in fighting bacterial infections. FATE also observed improvements in the cumulative incidence of engraftment of neutrophils and platelets, a type of blood cell involved in the prevention of bleeding; favorable 100-day survival; a low incidence of a serious complication known as graft-versus-host disease, or GvHD; and durable long-term hematopoietic reconstitution.

Based on these data, FATE initiated a Phase 2 clinical trial of ProHema in adult patients with hematologic malignancies in the fourth quarter of 2012.

More recently, FATE has demonstrated that it can further enhance the potency and efficacy of ProHema by incorporating an improved nutrient-rich media formulation, which FATE refers to its NRM formulation, in the manufacture of ProHema. In preclinical studies, ProHema manufactured using FATE's NRM formulation exhibited a more than two-fold improvement in engraftment over the prior media formulation.

In order to take advantage of this recent development, FATE elected to pause enrollment in the Phase 2 clinical trial to incorporate the NRM formulation.

The Phase 2 clinical trial of ProHema is currently active but not recruiting. On August 1, 2013, FATE submitted an IND amendment to the FDA, which contained preclinical and product development data to support the incorporation of the NRM formulation for the manufacture of ProHema. Based on recent communications with the FDA regarding this amendment, and expects to resume enrollment of the Phase 2 clinical trial of ProHema incorporating the NRM formulation in the first half of 2014, with the goal of generating full data from this trial in mid-2015.

FATE also expects to commence an additional clinical trial in children and adolescents with hematologic malignancies in 2014.

The therapeutic potential of HSCT procedures in LSDs has been demonstrated in clinical studies showing that many neurological manifestations of LSDs can be prevented or substantially reduced through early HSCT intervention.

These effects have been attributed to the ability of HSCs to home to and engraft within the CNS, where they give rise to cells that correct the underlying enzyme deficiency in the brain.

FATE has demonstrated in a preclinical model that the ex vivo modulation of HSCs increased the number of transplanted cells that home to the CNS.

FATE plans to initiate a clinical trial of ProHema in patients with LSDs in 2014, with the goal of generating data from this trial in 2015. FATE is also developing second-generation HSC therapeutics to further improve the CNS-homing ability of modulated HSCs.

Intellectual Property

FATE's intellectual property portfolio is currently composed of 46 issued patents and 174 patent applications that FATE licenses from academic and research institutions and 40 patent applications that FATE owns, and these patent and patent applications generally provide FATE with the rights to develop product candidates in the United States and worldwide.

This portfolio covers (I)the HSC modulation platform, including ProHema; (ii) the SSC modulation platform, including Wnt7a analogs and (III) other technologies, such as our iPSC technology. FATE believes that it has a significant intellectual property position and substantial know-how relating to the modulation of adult stem cells, including HSCs and SSCs.

Intellectual Property Relating to the HSC Modulation Platform and ProHema

FATE owns six families of pending U.S. and foreign patent applications covering our HSC modulation platform. This portfolio includes 14 pending applications relating to ProHema and other therapeutic compositions of stem cells that have been pharmacologically modulated to enhance their therapeutic properties, and methods of manufacturing the cellular compositions.

Applications in this portfolio include claims covering a therapeutic composition of human HSCs that Any U.S. patents issued from these applications will have statutory expiration dates between 2030 and 2034.

FATE has an exclusive license to a portfolio consisting of two families of issued patents and pending patent applications co-owned by the Children's Medical Center Corporation and The General Hospital Corporation.

FATE currently has exclusive rights to nine issued patents and 27 pending patent applications in the United States and worldwide relating to methods for promoting tissue growth or regeneration (including of the hematopoietic system) using modulators that up-regulate the prostaglandin signaling pathway or its downstream mediators.

FATE is currently the exclusive licensee of 45 issued or pending U.S. and non-U.S. patents or patent applications relating to ProHema and other therapeutic compositions of stem cells that have been pharmacologically modulated to enhance their therapeutic properties, methods of manufacturing the cellular compositions, and methods of promoting hematopoietic reconstitution, expansion and self-renewal using modulators that increase prostaglandin signaling activity.

FATE currently have exclusive licenses to 18 patents and patent applications relating to Wnt analogs, covering compositions of matter, processes for preparing such Wnt proteins and formulations, and the modulation of SSCs.

Competition

There are several clinical-stage development programs that seek to improve human UCBT through the use of ex vivo expansion technologies to increase the quantity of HSCs for use in HSCT or the use of ex vivo differentiation technologies to increase the quantity of hematopoietic progenitor cells for use in HSCT. Companies active in this area include, but are not limited to, Gamida Cell Ltd., Biotest Pharmaceuticals Corporation, Aldagen, Inc., a wholly-owned subsidiary of Cytomedix, Inc., Novartis Pharmaceuticals Corporation and Celerant Technology Corp.

Currently, there are no approved pharmaceutical products specifically developed for the treatment of muscular dystrophies. FATE is aware of several other companies developing therapies that are in various stages of development for the treatment of muscular dystrophies, including Prosensa Holding B.V., Sarepta Therapeutics Inc., PTC Therapeutics, Inc., Summit Corporation plc, Halo Therapeutics LLC, and Tivorsan Pharmaceuticals, Inc.

5% stockholders pre-IPO

ARCH Venture Fund VI, L.P., 16.8%
Entities affiliated with Polaris Venture Partners, 16.8%
Entities affiliated with Venrock, 16.8%
Entities affiliated with OVP Venture Partners, 15.4%
Entities affiliated with Fidelity Investments, 9.2%

Use of Proceeds

FATE expects to net $53 million from its IPO.

Proceeds are allocated as follows:

$24.0 million to fund research and development activities to advance the HSC modulation platform and the clinical and preclinical development of its product candidates, including the conduct of a Phase 2 clinical trial of ProHema in patients with orphan hematologic malignancies;

$16.0 million to fund research and development activities to advance the SSC modulation platform and the preclinical development of its product candidates, including the conduct of preclinical studies of Wnt7a analog product candidates; and

Remainder for working capital and general corporate purposes.

 

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Signup for our daily newsletter and get our best articles emailed right to you!

Results for fate
Terry
2 Aug 15 14:08:05
RT @TSTbiotech: Four Stem-Cell Stocks With Promise $FATE http://t.co/3224xDdmN6 http://t.co/YkeoYB0fDr
Nymeria
2 Aug 15 13:07:31
RT @TSTbiotech: Four Stem-Cell Stocks With Promise $FATE http://t.co/3224xDdmN6 http://t.co/YkeoYB0fDr
Mina Chen
2 Aug 15 09:55:46
RT @TSTbiotech: Four Stem-Cell Stocks With Promise $FATE http://t.co/3224xDdmN6 http://t.co/YkeoYB0fDr
Syed Samy
2 Aug 15 09:39:23
RT @TSTbiotech: Four Stem-Cell Stocks With Promise $FATE http://t.co/3224xDdmN6 http://t.co/YkeoYB0fDr
Charlie
2 Aug 15 08:59:03
RT @TSTbiotech: Four Stem-Cell Stocks With Promise $FATE http://t.co/3224xDdmN6 http://t.co/YkeoYB0fDr
stockmarketnow
2 Aug 15 08:51:50
RT TSTbiotech: Four Stem-Cell Stocks With Promise $FATE http://t.co/2jkykdbtNW; http://t.co/yElTJb17ao
Richie Moku
2 Aug 15 08:50:55
RT @TSTbiotech: Four Stem-Cell Stocks With Promise $FATE http://t.co/3224xDdmN6 http://t.co/YkeoYB0fDr
TheStreet
2 Aug 15 08:49:04
RT @TSTbiotech: Four Stem-Cell Stocks With Promise $FATE http://t.co/3224xDdmN6 http://t.co/YkeoYB0fDr
Argo
1 Aug 15 07:08:42
Weekly holdings by size: $blue $afmd $qure $mnta $adap $fate $pirs
InvestWithConf
31 Jul 15 20:35:02
$FATE is rated BUY, 77.1% upside by Wall Street analysts based on average ratings/targets http://t.co/CpIUrPt1qc http://t.co/e2EYVwsg85
James Stuart
31 Jul 15 19:49:45
$fate announces earnings next week. Maybe they will give guidance for the Prohema phase 2 readout date. great science and great management
J
31 Jul 15 10:45:02
@IncredibleTrade @ghoststock @super_trades back at you IT $FATE $AAOI so much value in chat
eastvillagetwt
31 Jul 15 09:52:49
RT @Dougallan1: $FATE $PSTI $CAPR $OCAT Video of bullish take by Raymond James analyst http://t.co/KIBLOynZwK
assailed
31 Jul 15 09:44:20
$FATE long
Will_B
31 Jul 15 06:36:17
RT @BrandonFishman: $fate is ready to take off. This stock will double in the next 6 months $fb to 120. $aapl to $150
brandonfishman
31 Jul 15 06:24:16
$fate is ready to take off. This stock will double in the next 6 months $fb to 120. $aapl to $150
WatchTheFunds
31 Jul 15 00:30:01
$FATE Institutional ownership up 1.05% Q/Q, with 102,598 net purchase http://t.co/MMd26aE8Yd http://t.co/S1ELMygVhV
Yuppy
30 Jul 15 23:03:09
RT @super_trades: http://t.co/TarXgk6T2z $2,682.87 profit $FATE 2 days ago, see my track record & realtime alerts: http://t.co/8B6wB2t5qz
Joe Librescu
30 Jul 15 21:21:29
@danwardbio and $FATE please :)
James Stuart
30 Jul 15 16:13:40
$fate http://t.co/hu9RZ6nji4 Such a promising company with an amazing potential
Timothy Sykes
30 Jul 15 15:10:27
RT @super_trades: http://t.co/TarXgk6T2z $2,682.87 profit $FATE 2 days ago, see my track record & realtime alerts: http://t.co/8B6wB2t5qz
Profit.ly
30 Jul 15 15:10:19
RT @super_trades: http://t.co/TarXgk6T2z $2,682.87 profit $FATE 2 days ago, see my track record & realtime alerts: http://t.co/8B6wB2t5qz
Investimonials.com
30 Jul 15 15:10:05
RT @super_trades: http://t.co/TarXgk6T2z $2,682.87 profit $FATE 2 days ago, see my track record & realtime alerts: http://t.co/8B6wB2t5qz
@super_trades
30 Jul 15 15:00:02
http://t.co/TarXgk6T2z $2,682.87 profit $FATE 2 days ago, see my track record & realtime alerts: http://t.co/8B6wB2t5qz
TheStreet Biotech
30 Jul 15 11:51:04
Four Stem-Cell Stocks With Promise $FATE http://t.co/3224xDdmN6 http://t.co/YkeoYB0fDr
Douglas Allan
30 Jul 15 09:50:15
$FATE $PSTI $CAPR $OCAT Video of bullish take by Raymond James analyst http://t.co/KIBLOynZwK
InvestWithConf
30 Jul 15 06:58:02
$FATE is rated BUY, 75.8% upside by Wall Street analysts based on average ratings/targets http://t.co/CpIUrPt1qc http://t.co/WFksa5DVHs
Will_B
29 Jul 15 14:19:10
RT @GNWLive: Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2015 Financial Results on August 5 $FATE http://t.co/dfa…
GNWLive
29 Jul 15 13:03:35
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2015 Financial Results on August 5 $FATE http://t.co/dfa2srwFvH
MyAllies Trading
29 Jul 15 13:02:52
$FATE Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2015 Financial Results on August 5... http://t.co/2UEEe5IZpi
Joe Librescu
29 Jul 15 13:02:40
@techwhitepapers $FATE is also developing a PD-L1 programmed immuno-regulatory cellular therapeutic for the treatment of autoimmune diseases
Joe Librescu
29 Jul 15 13:02:18
$FATE leveraging its proprietary induced pluripotent stem cell platform to develop natural killer cell and T cell cancer immunotherapeutics
WatchTheFunds
29 Jul 15 11:51:01
$FATE Institutional ownership up 1.05% Q/Q, with 102,598 net purchase http://t.co/MMd26aE8Yd http://t.co/AoUz8Idb93
Joe Librescu
29 Jul 15 11:23:02
@AmolDJadhav thought after entities.. hold and build positions in $afmd $vblt $cala and $fate .
Julia Skripka-Serry
29 Jul 15 09:47:56
Just realized what $FATE actually does.. ew http://t.co/Bt6KctZoz7
Kristina Duering
29 Jul 15 09:32:02
RT @techwhitepapers: $fate partnered with Univ of Minnesota to develop NK cells immuno oncology drugs. here is t potential http://t.co/G5dn…
Jacob Jackson
29 Jul 15 08:21:21
@EBUYUKARSLAN Casino investment $FATE http://t.co/4XePwV3RCD
EB Trade
29 Jul 15 08:16:43
$RJET was nice run without news. I think Short was covering.. Lets make the run for $Cala and $Pes next:) Also watching $fate for any bounce
Will_B
29 Jul 15 06:32:14
RT @techwhitepapers: $fate partnered with Univ of Minnesota to develop NK cells immuno oncology drugs. here is t potential http://t.co/G5dn…
Kristina Duering
29 Jul 15 03:55:49
RT @techwhitepapers: the lights where yesterday on $nk.. but it has forgotten about $Fate huge news of not long ago in the field http://t.c…
Joe Librescu
29 Jul 15 03:48:11
@dhovekamp42 but yes for sure for sure for sure $afmd and $fate and a slew others are undervalued.
Joe Librescu
29 Jul 15 03:09:31
$fate partnered with Univ of Minnesota to develop NK cells immuno oncology drugs. here is t potential http://t.co/G5dnmv4Rhw
Joe Librescu
29 Jul 15 03:01:07
@techwhitepapers $fate Jeff Miller in May 2015 presented "Enhancing NK cell function and making them antigen specific to treat cancer"
Joe Librescu
29 Jul 15 02:59:19
@techwhitepapers @NK symposium in germany $afmd will participate; $fate partner Jeff Miller is a confirmed speaker http://t.co/zmjbWiIwld
Joe Librescu
29 Jul 15 02:57:02
@techwhitepapers $Fate partner Jeff Miller http://t.co/sr6oAnJulF
Joe Librescu
29 Jul 15 02:55:08
@techwhitepapers $fate 's cell programming technology will optimize NK cell persistence t boost development of programmed “adaptive” theraps
Joe Librescu
29 Jul 15 02:53:28
@techwhitepapers $Fate in principle partnered with world renowned NK Cells scientist Jeff Miller . what will this partnership yield?
Joe Librescu
29 Jul 15 02:52:22
the lights where yesterday on $nk.. but it has forgotten about $Fate huge news of not long ago in the field http://t.co/i8iC8QfpZr
Joe Librescu
29 Jul 15 02:46:34
@dhovekamp42 not sure.. either way $nk despite overvaluation and all it is a good catalyst for NK cells related drug developers $afmd $Fate
Joe Librescu
28 Jul 15 23:15:52
@stb8444 i wouldnt put money on that Scott because $blue is very expansive compared to say $fate and has partnerships and is hematogical
				
				
By  +Follow September 18, 2013 7:01AM
Share:

Comments

 

blog comments powered by Disqus

 Today's Must Reads

Beyond Twitter: 5 Small-Cap Tech Plays Nobody’s Talking About


Will the Fed Continue Its Track Record of Unprecedented Moves?

Facebook versus Google: Who Rules the Internet?

Are These the Worst Business Documentaries on Netflix?


Saving the

Small-Cap Market

 

Small-cap stocks offer investors many benefits, ranging from higher growth potential to overlooked value opportuni... in Equities.com's Hangs on LockerDome

About us

Equities.com is an advanced financial data portal and social network designed to connect self-directed investors with the world’s most innovative startup and small cap companies. Through our in-depth coverage of small cap markets, comprehensive research and stock valuation reports, state of the art issuer products, and world class events, Equities.com provides the social tools and insight that drive tomorrow’s investment relationships and opportunities.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.

Login or Register

LOG IN